Nanomerics today announced that the Canadian Intellectual Property Office will allow key patent application underpinning its enkephalin pain therapeutic (patent application number - CA2754140) to proceed to grant. This patent supports Nanomerics’ pain therapeutics, including NM0127 and provides further assurances to potential partners on patent protection in key markets. Nanomerics will continue to defend its assets with key patent applications and ongoing patent prosecution. This is a major component of its business strategy. Said Andreas Schatzlein, Chief Executive Officer of Nanomerics, “we are pleased that we are attracting favourable responses to our patent applications in all jurisdictions and we were delighted to receive this notice as Canada is one of the major pharmaceutical markets."